Molecular PET imaging in multicenter Alzheimer's therapeutic trials: Current trends and implementation strategies

Expert Review of Neurotherapeutics

Volumn 11, Issue 12, 2011, Pages 1783-1793

  Seibyl, John ^a,b   Zubal, Ihor George ^a,b   Jennings, Danna ^a   Marek, Kenneth ^a,b   Doraiswamy, P Murali ^c  

^a DUKE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; amyloid b; multicenter trials; PET

Indexed keywords

AAC 001; ACC 011; ACI 24; AMYLOID PROTEIN; AVAGACESTAT; BAPINEUZUMAB; FLORBETABEN; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; GANTENERUMAB; IMMUNOLOGICAL ADJUVANT; MABT 5102A; NOOTROPIC AGENT; PITTSBURGH COMPOUND B; PLACEBO; QS 21; RO 4909832; SEMAGACESTAT; SOLANEZUMAB; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BRAIN SCINTISCANNING; DRUG HALF LIFE; DRUG UPTAKE; HUMAN; IMAGE PROCESSING; IMAGE QUALITY; IMMUNOTHERAPY; MOLECULAR IMAGING; MULTICENTER STUDY (TOPIC); NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; QUALITY CONTROL; RADIOLOGIST; REVIEW; STAFF TRAINING; TREATMENT RESPONSE;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BRAIN; DISEASE PROGRESSION; HUMANS; MULTICENTER STUDIES AS TOPIC; POSITRON-EMISSION TOMOGRAPHY;

EID: 81755187625     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.168     Document Type: Review

References (30)

1. Marek K, Jennings D, Tamagnan G, Seibyl J. Biomarkers for Parkinsons disease: tools to assess Parkinsons disease onset and progression. Ann. Neurol. 64(Suppl. 2), S111-S121 (2008).
2. Walhovd KB, Fjell AM, Brewer J et al. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am. J. Neuroradiol. 31(2), 347-354 (2010).
3. Ravina B, Tanner C, Dieuliis D et al. A longitudinal program for biomarker development in Parkinsons disease: a feasibility study. Mov. Disord. 24(14), 2081-2090 (2009).
4. Sojkova J, Resnick SM. In vivo human amyloid imaging. Curr. Alzheimer Res. 8(4), 366-372 (2011).
5. Nelissen N, Van Laere K, Thurfjell L et al. Phase I study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J. Nucl. Med. 50(8), 1251-1259 (2009).
6. Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ. Pre-clinical detection of Alzheimers disease using FDG-PET, with or without amyloid imaging. J. Alzheimers Dis. 20(3), 843-854 (2010).
7. Rowe CC, Ackerman U, Browne W et al. Imaging of amyloid beta in Alzheimers disease with 18F-βAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 7(2), 129-135 (2008).
8. Wong DF, Rosenberg PB, Zhou Y et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J. Nucl. Med. 51(6), 913-920 (2010).
9. Vandenberghe R, Van Laere K, Ivanoiu A et al.18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a Phase 2 trial. Ann. Neurol. 68(3), 319-329 (2010).
10. Hampel H, Frank R, Broich K et al. Biomarkers for Alzheimers disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Dis. 9(7), 560-574 (2010).
11. Joshi A, Koeppe RA, Fessler JA. Reducing between scanner differences in multi-center PET studies. Neuroimage 46(1), 154-159 (2009).
12. Jack CR Jr, Bernstein MA, Fox NC et al. The Alzheimers Disease Neuroimaging Initiative (ADNI): MRI methods. J. Magn. Reson. Imaging 27(4), 685-691 (2008).
13. Alzheimers Disease Neuroimaging Initiative (ADNI). PET Technical Procedures Version 9.5. ADNI, CA, USA, 1-60 (2006).
14. Seibyl J, Marek K, Zubal IG. The role of the core imaging laboratory in multicenter trials. Semin. Nucl. Med. 40(5), 338-346 (2010).
15. Thomas BA, Erlandsson K, Modat M et al. The importance of appropriate partial volume correction for PET quantification in Alzheimers disease. Eur. J. Nucl. Med. Mol. Imaging 38(6), 1104-1119 (2011).
16. Tzourio-Mazoyer N, Landeau B, Papathanassiou D et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain Neuroimage 15, 273-289 (2002).
17. Haense C, Herholz K, Jagust WJ, Heiss WD. Performance of FDG PET for detection of Alzheimers disease in two independent multicentre samples (NEST-DD and ADNI). Dement. Geriatr. Cogn. Disord. 28(3), 259-266 (2009).
18. Landau SM, Harvey D, Madison CM et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol. Aging 32(7), 1207-1218 (2011).
19. Senjem ML, Gunter JL, Shiung MM, Petersen RC, Jack CR Jr. Comparison of different methodological implementations of voxel-βased morphometry in neurodegenerative disease. Neuroimage 26(2), 600-608 (2005).
20. Mormino EC, Kluth JT, Madison CM et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 132(Pt 5), 1310-1323 (2009).
21. Jack CR Jr, Vemuri P, Wiste HJ et al. Evidence for ordering of Alzheimer disease biomarkers. Arch. Neurol. doi:20111831-10 (2011) (Epub ahead of print).
22. Morris JC, Roe CM, Grant EA et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol. 66(12), 1469-1475 (2009).
23. Engler H, Forsberg A, Almkvist O et al. Two year follow up of amyloid deposition in patients with Alzheimers disease. Brain 129(Pt 11), 2856-2866 (2006).
24. Rinne J, Brooks D, Rossor M et al. 11C-PIB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimers disease treated with bapineuzumab: a Phase 2, double-βlind, placebo-controlled, ascending-dose study. Lancet Neurol. 9, 363-372 (2010).
25. Clark CM, Schneider JA, Bedell BJ et al. AV45-A07 Study Group. Use of florbetapir- PET for imaging beta-amyloid pathology. JAMA 305(3), 275-283 (2011).
26. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimers disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 32(4), 486-510 (2005).
27. Shin J, Lee S, Kim SJ, Kim SH, Cho S, Kim YB. Voxel-βased analysis of Alzheimers disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG. Neuroimage 52(2), 488-496 (2010).
28. Ishii K, Kanda T, Uemura T et al. Computer-assisted diagnostic system for neurodegenerative dementia using brain SPECT and 3D-SSP. Eur. J. Nucl. Med. Mol. Imaging 36(5), 831-840 (2009).
29. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimers disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J. Nucl. Med. 36(7), 1238-1248 (1995).
30. Zubal IG, Early M, Yuan O, Jennings D, Marek K, Seibyl JP. Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinsons disease patients. J. Nucl. Med. 48(6), 857-864 (2007).